NEW YORK (GenomeWeb) – Biocartis said yesterday that it has signed a development agreement with Genomic Health to develop an in vitro diagnostic version of the Oncotype DX Genomic Prostate Score (GPS) Test.
The agreement expands on a previous partnership to develop an IVD version of Genomic Health's Oncotype DX Breast Recurrence Score test on Biocarts' Idylla platform.
As part of the expanded collaboration, Genomic Health has exclusive rights to develop and commercialize Oncotype DX GPS on Idylla. The partners plan to begin developing the test in early 2019.
In addition, Genomic Health will pay €2.5 million ($2.8 million) to Biocartis, which it plans to expense in Q4 2018. Upon commercialization, Genomic Health will make royalty payments to Biocartis based on net sales.
"Expanding our collaboration to initiate development of the Oncotype DX GPS test on this fully automated sample-to-answer platform reflects our confidence in the Idylla platform as a best-in-class solution to accelerate access to Oncotype tests around the world," Genomic Health Chief Operating Officer Frederic Pla said in a statement.